Upside case
Bull case
$285+187.4%
RVTY would need investors to value it at roughly 53x earnings — about 34x more generous than today's 18x forward P/E. That requires meaningful multiple expansion on top of continued earnings growth.
Analysis OverviewBuyUpdated May 1, 2026
Revvity, Inc. (RVTY) Stock Analysis
Wall Street verdict, consensus price target, and analyst rating breakdown — everything needed to frame the risk/reward at today's price.
Analyst consensus
Buy
Covering
29
analysts
15 bullish · 0 bearish · 29 covering RVTY
Strong Buy
0
Buy
15
Hold
14
Sell
0
Strong Sell
0
Consensus Target
$112
+12.9% vs today
Scenario Range
$74 – $285
Model bear to bull value window
Coverage
29
Published analyst ratings
Valuation Context
18.4x
Forward P/E · Market cap $11.1B
RVTY price targets
Three scenarios for where RVTY stock could go
Current
~$99
Confidence
54 / 100
Updated
May 1, 2026
Where we are now
Current · $99
Bear
$74
Base
$153
Bull
$285
Market caseClosest to today
Base case
$153+54.6%
At 28x on FY1 earnings, the base case reflects a reasonable but not stretched valuation. It prices in continued growth without assuming an exceptional setup.
Stress case
Bear case
$74-25.4%
If investor confidence fades or macro conditions deteriorate, a 5x multiple contraction could push RVTY down roughly 25% from where it trades now.
Not financial advice. Model confidence reflects internal scenario assumptions, not a guarantee of returns. Past performance does not predict future results.
Revvity, Inc.
RVTY · NYSEHealthcareMedical - Diagnostics & ResearchDecember year-end
Revvity is a healthcare technology company that provides instruments, reagents, software, and services for life sciences research, diagnostics, and applied markets. It generates revenue through two main segments: Discovery & Analytical Solutions (~60% of sales) serving research and industrial customers, and Diagnostics (~40%) focused on genetic disorder and infectious disease testing. The company's competitive advantage lies in its integrated platform approach—combining hardware, consumables, and software—which creates recurring revenue streams and high customer switching costs.
Market Cap
$11.1B
Revenue TTM
$2.9B
Net Income TTM
$241M
Net Margin
8.3%
RVTY Revenue and Earnings Performance
Quarterly beat-or-miss track record against analyst estimates, plus forward revenue and EPS outlook for the next two fiscal years.
EPS Beat Rate
92%Exceptional
12 quarters tracked
Revenue Beat Rate
75%Exceptional
vs consensus estimates
Avg EPS Surprise
+5.4%
above Street consensus
Beat / Miss Record
BeatMissLeft = EPS · Right = Revenue
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Last 4 Quarters
EPS beats: 4 of 4Q3 2025
EPS
$1.18/$1.14
Revenue
$720M/$700M
Q4 2025
EPS
$1.18/$1.14
Revenue
$699M/$699M
Q1 2026
EPS
$1.70/$1.57
Revenue
$772M/$765M
Q2 2026
EPS
$1.06/$1.02
Revenue
$711M/$704M
| Quarter | EPS (Actual / Est) | EPS Surprise | Revenue (Actual / Est) | Rev Surprise |
|---|---|---|---|---|
| Q3 2025 | $1.18/$1.14 | +3.5% | $720M/$700M | +2.9% |
| Q4 2025 | $1.18/$1.14 | +3.5% | $699M/$699M | -0.1% |
| Q1 2026 | $1.70/$1.57 | +8.3% | $772M/$765M | +0.9% |
| Q2 2026 | $1.06/$1.02 | +3.9% | $711M/$704M | +1.0% |
FY1–FY2 Estimates
Revenue Outlook
FY1
$2.9B
+0.3% YoY
FY2
$2.9B
+0.5% YoY
EPS Outlook
FY1
$3.19
+48.2% YoY
FY2
$3.21
+0.8% YoY
Trailing FCF (TTM)$505M
FCF Margin: 17.4%
Next Earnings
—
Expected EPS
—
Expected Revenue
—
RVTY beat EPS estimates in 4 of 4 tracked quarters. A perfect track record raises the bar for the upcoming report.
RVTY Revenue Breakdown by Segment
Product and geographic revenue mix from the latest annual disclosure, with year-over-year growth by segment.
Latest disclosure
FY 2025
Total disclosed revenue $2.9B
Product Mix
Latest annual revenue by segment or product family
Life Sciences
50.1%
+14.1% YoY
Tap, hover, or focus a slice to inspect segment detail.
Geographic Mix
Latest annual revenue by reported region
Other International
59.5%
-0.8% YoY
Tap, hover, or focus a slice to inspect segment detail.
Life Sciences is the largest disclosed segment at 50.1% of FY 2025 revenue, up 14.1% YoY.
Other International is the largest reported region at 59.5%, down 0.8% YoY.
RVTY Valuation Snapshot
Current multiples compared to the S&P 500, the company's sector, and its own five-year average.
Relative Value Signal
Significantly Undervalued
Fair value est. $143 — implies +65.3% from today's price.
Upside to Fair Value
65.3%
potential upside
Deep DiscountFair ValueVery Expensive
vs S&P 500 Trailing P/E
RVTY
47.6x
vs
S&P 500
25.2x
+89% premium
vs Healthcare Trailing P/E
RVTY
47.6x
vs
Healthcare
22.1x
+115% premium
vs RVTY 5Y Avg P/E
Today
47.6x
vs
5Y Average
37.3x
+28% premium
Forward PE
18.4x
S&P 500
19.1x
-4%
Healthcare
19.0x
-4%
5Y Avg
—
—
Trailing PE
47.6x
S&P 500
25.2x
+89%
Healthcare
22.1x
+115%
5Y Avg
37.3x
+28%
PEG Ratio
—
S&P 500
1.75x
—
Healthcare
1.52x
—
5Y Avg
—
—
EV/EBITDA
20.8x
S&P 500
15.3x
+36%
Healthcare
14.1x
+47%
5Y Avg
19.0x
+9%
Price/FCF
21.8x
S&P 500
21.3x
+2%
Healthcare
18.7x
+17%
5Y Avg
23.6x
-8%
Price/Sales
3.9x
S&P 500
3.1x
+24%
Healthcare
2.8x
+36%
5Y Avg
5.1x
-23%
Dividend Yield
0.29%
S&P 500
1.88%
-84%
Healthcare
1.40%
-79%
5Y Avg
0.23%
+28%
| Metric | RVTY | S&P 500 | Healthcare | 5Y Avg RVTY |
|---|---|---|---|---|
| Forward PE | 18.4x | 19.1x | 19.0x | — |
| Trailing PE | 47.6x | 25.2x+89% | 22.1x+115% | 37.3x+28% |
| PEG Ratio | — | 1.75x | 1.52x | — |
| EV/EBITDA | 20.8x | 15.3x+36% | 14.1x+47% | 19.0x |
| Price/FCF | 21.8x | 21.3x | 18.7x+17% | 23.6x |
| Price/Sales | 3.9x | 3.1x+24% | 2.8x+36% | 5.1x-23% |
| Dividend Yield | 0.29% | 1.88% | 1.40% | 0.23% |
RVTY trades above S&P 500 benchmarks on 3 of 5 measured multiples — is elevated on some multiples, but competitive on others — a mixed valuation picture.
Forward P/E and PEG reflect analyst consensus estimates. Historical averages use trailing ratios where forward data is unavailable.S&P 500 and sector benchmarks both use trailing median P/E — similar readings indicate the broader index and sector are priced alike.
Open valuation toolRVTY Financial Health
Verdict
Adequate
RVTY generates $505M in free cash flow at a 17.4% margin — returns 7.7% of market cap to shareholders annually.
Cash Engine
Revenue, margins, and cash generation
Revenue (TTM)
Trailing-twelve-month sales base
$2.9B
Revenue Growth
TTM vs prior year
+4.8%
Gross Margin
Gross profit as a share of revenue
51.4%
Operating Margin
Operating income divided by revenue
12.4%
Net Margin
Net income divided by revenue
8.3%
EPS (TTM)
Diluted earnings per share, trailing twelve months
$2.15
Free Cash Flow (TTM)
Cash generation after capex
$505M
FCF Margin
FCF as share of revenue — the primary cash quality signal
17.4%
Capital Quality
ROIC, leverage, and debt serviceability
ROIC
Return on invested capital — primary competitive quality signal
2.7%
ROA
Return on assets, trailing twelve months
2.0%
Cash & Equivalents
Liquid assets on the balance sheet
$920M
Net Debt
Total debt minus cash
$2.6B
Debt Serviceability
Net debt as a multiple of annual free cash flow
5.1× FCF
~5.1 years to full repayment at current FCF run-rate
ROE
Return on equity, trailing twelve months
3.3%
Shareholder Returns
How capital is returned to owners
Total shareholder yield
7.7%
Dividend
0.3%
Buyback
7.4%
Share Repurchases
Trailing buyback outflow — dollar magnitude of capital returned
$821M
Dividend / Share
Annualized trailing dividend per share
$0.29
Payout Ratio
Share of earnings distributed as dividends
13.6%
Shares Outstanding
Declining as buybacks retire shares
112M
All figures from the trailing twelve months. ROIC uses invested capital (equity + net debt).
Open full ratios pageRVTY Stock Risk Factors
Key factors that could pressure the stock price, compress the multiple, or weigh on future results.
AI analysis · updated April 29, 2026
High Risk
Macroeconomic and Global Environment
Fluctuations in the global economic and political environments, including tariff increases and potential government shutdowns affecting regulatory bodies like the FDA, can disrupt supply chains, lead to product shortages, and impact operational efficiency.
High Risk
China Market Exposure
Revvity's diagnostics exposure in China is a significant wildcard risk factor, with revenues from China projected to decline significantly as a percentage of total revenue due to policy and funding pressures.
Medium
Market Demand and Growth
A low-single-digit organic growth outlook and concerns about waning demand in core businesses suggest that Revvity may need to improve its products, pricing, or go-to-market strategies, negatively impacting its financial outlook.
Medium
Regulatory and Government Factors
Government shutdowns impacting regulatory agencies like the FDA can delay development activities, regulatory filings, and manufacturing operations, potentially affecting commercial success.
Medium
Operational and Financial Performance
A shrinking adjusted operating margin and concerns about the company's ability to protect margins over time are factors to monitor, despite positive cash flows that provide some de-risking.
Lower
Competition
The development and commercialization of new medicines and technologies are highly competitive, with substantial competition from major pharmaceutical, specialty pharmaceutical, and biotechnology companies.
Lower
Product Development and Innovation
The failure to introduce new products in a timely manner or the inability to achieve market acceptance for new medicines can adversely affect the business.
Lower
Analyst Sentiment and Investor Caution
Recent analyst caution and a shift to a more neutral stance by some firms can weigh on stock momentum, contributing to a share price drop.
These are risk mechanisms, not predictions. The key question is which would force a cut to earnings estimates or a lower multiple than the market currently prices in.
Why RVTY Stock Could Outperform
Structural drivers behind the upside case and why the stock could outperform over the next 12 months.
AI analysis · updated April 29, 2026
Strategic Transformation and Innovation
Revvity is actively shifting towards higher-margin software and reagents, exemplified by its new AI-enabled oncology tools and cloud-native Signals BioDesign molecular cloning software. These offerings aim to streamline research workflows for pharma, biotech, and academic labs by integrating advanced imaging, automation, and AI-enabled analytics.
Software Growth
The Signals software franchise is a key growth engine, with the company deepening its presence in cloud-native, AI-ready biologics design. This focus on recurring, higher-margin software is seen as a potential offset to pressures in other segments.
Diversified Portfolio and Market Position
Revvity benefits from a diversified portfolio that includes its high-growth Signals software, as well as a strong presence in life sciences and immunodiagnostics. The company is also enhancing its competitive position in the US market through share gains in autoimmune testing.
Financial Outlook and Guidance
While acknowledging market uncertainties, Revvity's guidance for 2026 is considered conservative, with potential for upside. The company has demonstrated revenue growth, with a 3.67% increase in 2025 compared to the previous year.
Operational Rigor and Margin Expansion
The company emphasizes operational rigor to support margin expansion and strong cash flow. Projections indicate margin expansion to 28% in 2025.
A real bull case compounds — each driver matters most when it strengthens margins, supports capital returns, and keeps the company above the market's minimum growth bar simultaneously.
RVTY Stock Price Performance
52-week range context and price returns across multiple time horizons. Dividend contribution is shown separately in the Capital Return section.
Current Price
$99.09
52W Range Position
48%
52-Week Range
Current price plotted between the 52-week low and high.
52-Week Low
$81.22
+22.0% from the low
52-Week High
$118.30
-16.2% from the high
1 Month
+12.19%
3 Month
-2.46%
YTD
+1.0%
1 Year
+9.6%
3Y CAGR
-8.2%
5Y CAGR
-6.3%
10Y CAGR
+6.2%
Range context matters because valuation compression and earnings misses rarely hit from the same starting point. A stock already far below its high can still fall, but it is no longer carrying the same embedded optimism as one pressing a fresh peak.
RVTY vs Peers
Valuation, growth, and margin comparison against the closest publicly traded peers for this company.
Peer Set
Accurate peer set
Forward PE
18.4x
vs 24.3x median
-24% below peer median
Revenue Growth
+0.3%
vs +3.8% median
-92% below peer median
Net Margin
8.3%
vs 11.9% median
-30% below peer median
| Company | Mkt Cap | Fwd PE | Rev Grw | Margin | Rating | Upside |
|---|---|---|---|---|---|---|
RVT RVTY Revvity, Inc. | $11.1B | 18.4x | +0.3% | 8.3% | Buy | +12.9% |
WAT WAT Waters Corporation | $22.8B | 24.3x | +33.4% | 11.9% | Hold | +15.2% |
BRK BRKR Bruker Corporation | $6.4B | 20.0x | +10.4% | -0.8% | Buy | +23.2% |
MTD MTD Mettler-Toledo International Inc. | $27.0B | 28.6x | +3.8% | 21.6% | Hold | +12.2% |
BIO BIO Bio-Rad Laboratories, Inc. | $7.0B | 25.2x | -0.1% | 6.5% | Buy | +20.6% |
HOL HOLX Hologic, Inc. | $17.0B | 17.2x | +0.3% | 13.2% | Hold | +3.9% |
This peer comparison reflects companies with similar business models, product lines, or market positioning, supplemented by industry grouping when direct matches are limited.
RVTY Dividend and Capital Return
RVTY returns capital mainly through $821M/year in buybacks (7.4% buyback yield), with a modest 0.29% dividend — combining for 7.7% total shareholder yield.
Dividend SustainableFCF Well Covered
Total Shareholder Yield
7.7%
Dividend + buyback return per year
Buyback Yield
7.4%
Dividend Yield
0.29%
Payout Ratio
13.6%
How RVTY Splits Its Return
Buyback 7.4%
Dividend 0.29%Buybacks 7.4%
Dividend Profile
Yield, cadence, and growth quality
Dividend / Share
Trailing annualized cash dividend
$0.29
Growth Streak
Consecutive years of dividend increases
4Y
3Y Div CAGR
0.0%
5Y Div CAGR
0.0%
Ex-Dividend Date
—
Payment Cadence
Quarterly
4 payments over the last 12 months
Buyback Engine
How much per-share support comes from repurchases
Repurchases (TTM)
Cash used for buybacks in the latest trailing period
$821M
Estimated Shares Retired
8M
Approx. Share Reduction
7.4%
Shares Outstanding
Current diluted share count from the screening snapshot
112M
At 7.4%/year, buybacks mechanically lift EPS even with flat earnings — each remaining share represents a slightly larger piece of the company.
| Year | Div / Share | YoY Grw | BB Yield | Total Yield |
|---|---|---|---|---|
| 2026 | $0.14 | — | — | — |
| 2025 | $0.28 | 0.0% | 7.5% | 7.8% |
| 2024 | $0.28 | 0.0% | 2.7% | 2.9% |
| 2023 | $0.28 | 0.0% | 2.9% | 3.1% |
| 2022 | $0.28 | 0.0% | 0.5% | 0.7% |
FAQ
7 questionsRVTY Investor Questions
Common questions answered from live analyst data and company financials.
01Is Revvity, Inc. (RVTY) stock a buy or sell in 2026?
Revvity, Inc. (RVTY) is rated Buy by Wall Street analysts as of 2026. Of 29 analysts covering the stock, 15 rate it Buy or Strong Buy, 14 rate it Hold, and 0 rate it Sell or Strong Sell. The consensus 12-month price target is $112, implying +12.9% from the current price of $99. The bear case scenario is $74 and the bull case is $285.
02What is the RVTY stock price target for 2026?
The Wall Street consensus price target for RVTY is $112 based on 29 analyst estimates. The high-end target is $129 (+30.2% from today), and the low-end target is $95 (-4.1%). The base case model target is $153.
03Is Revvity, Inc. (RVTY) stock overvalued in 2026?
RVTY trades at 18.4x times forward earnings. The stock trades at a notable premium to the broad market, which is typical for businesses with strong free cash flow and above-average growth expectations. Based on current multiples versus the peer group, the relative model signals significantly undervalued. Whether the stock is over or undervalued ultimately depends on whether consensus earnings estimates are achievable.
04What are the main risks for Revvity, Inc. (RVTY) stock in 2026?
The primary risks for RVTY in 2026 are: (1) Macroeconomic and Global Environment — Fluctuations in the global economic and political environments, including tariff increases and potential government shutdowns affecting regulatory bodies like the FDA, can disrupt supply chains, lead to product shortages, and impact operational efficiency. (2) China Market Exposure — Revvity's diagnostics exposure in China is a significant wildcard risk factor, with revenues from China projected to decline significantly as a percentage of total revenue due to policy and funding pressures. (3) Market Demand and Growth — A low-single-digit organic growth outlook and concerns about waning demand in core businesses suggest that Revvity may need to improve its products, pricing, or go-to-market strategies, negatively impacting its financial outlook. Each factor has the potential to pressure earnings or compress the stock's valuation multiple.
05What is Revvity, Inc.'s revenue and earnings forecast?
Analyst consensus estimates RVTY will report consensus revenue of $2.9B (+0.3% year-over-year) and EPS of $3.19 (+48.2% year-over-year) for the upcoming fiscal year. The following year, analysts project $2.9B in revenue.
06When does Revvity, Inc. (RVTY) report its next earnings?
A confirmed upcoming earnings date for RVTY is not yet available. Check the Earnings section above for the most recent quarterly report dates and forward estimates.
07How much free cash flow does Revvity, Inc. generate?
Revvity, Inc. (RVTY) generated $505M in free cash flow over the trailing twelve months — a free cash flow margin of 17.4%. RVTY returns capital to shareholders through dividends (0.3% yield) and share repurchases ($821M TTM).